Top

Published in:

01-05-2010 | Clinical Research

The Relationships Between IGF-1 and CRP, NO, Leptin, and Adiponectin During Weight Loss in the Morbidly Obese

Authors: Eva Pardina, Roser Ferrer, Juan Antonio Baena-Fustegueras, Albert Lecube, Jose Manuel Fort, Víctor Vargas, Roberto Catalán, Julia Peinado-Onsurbe

Published in: Obesity Surgery | Issue 5/2010

Abstract

Background

The relationship between C-reactive protein (CRP), nitric oxide (NO), leptin, adiponectin, and insulin growth factor 1 (IGF-1) is poorly defined in morbidly obese patients before and after gastric bypass and, in some cases, is controversial.

Methods

We examined the plasma of 34 morbidly obese patients before and 1, 6, and 12 months after Roux-en-Y gastric bypass surgery.

Results

Obese people had more CRP (21.3 ± 1.8 μg/ml) and leptin (36.9 ± 4.0 ng/ml) than those in the control group (nonobese people: CRP = 6.9 ± 0.9 μg/ml, p < 0.0001; leptin = 7.5 ± 0.4 ng/ml, p < 0.0001). However, they had less NO (30.4 ± 2.7 nmol/ml), IGF-1 (77.5 ± 6.6 ng/ml), and adiponectin (11.1 ± 1.0 μg/ml) than those in the control group (NO = 45.8 ± 3.9 nmol/ml, p = 0.0059; IGF-1 = 202.0 ± 12.0 ng/ml, p < 0.0001; adiponectin = 18.0 ± 2.0 μg/ml, p < 0.0001). During weight loss, the amount of CRP and leptin decreased until they reached the nonobese values, but the level of NO remained lower than in nonobese people, even 1 year after surgery. The linear regression slopes were negative and very significant for leptin (p = 0.0005) and CRP (p = 0.0018) but were less significant for NO (p = 0.0221). IGF-1 displayed a very good linear regression (both negative and significant) with some anthropometric parameters, including body mass index (p = 0.0025), total fat (p = 0.0177), and the percentage of fat (p < 0.0001).

Conclusion

For the first time, we report the relationship between IGF-1 and CRP, NO, leptin, and adiponectin. For all these parameters, the best and most widely demonstrated improvements in comorbidities before and during weight loss in morbid obesity were associated with CRP and leptin.

Black PH. The inflammatory consequences of psychologic stress: relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II. Med Hypotheses. 2006;67:879–91.CrossRefPubMed

Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–30.PubMed

Engstrom G, Hedblad B, Stavenow L, et al. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes. 2003;52:2097–101.CrossRefPubMed

Morley JJ, Kushner I. Serum C-reactive protein levels. C-reactive protein and the plasma protein response to tissue injury. Annals NY Acad Sci. 1982;389:406–17.CrossRef

Davda RK, Stepniakowski KT, Lu G, et al. Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism. Hypertension. 1995;26:764–70.PubMed

Vincent HK, Powers SK, Dirks AJ, et al. Mechanism for obesity-induced increase in myocardial lipid peroxidation. Int J Obes Relat Metab Disord. 2001;25:378–88.CrossRefPubMed

Sledzinski T, Sledzinski M, Smolenski RT, et al. Increased serum nitric oxide concentration after bariatic surgery: a potential mechanism for cardiovascular benefit. Obes Surg. 2010;20(2):204–10.

Maniscalco M, de Laurentils G, Zedda A, et al. Exhaled nitric oxide in severe obesity: effect of weight loss. Respir Physiol Neurobiol. 2007;156(3):370–3.

Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292–5.CrossRefPubMed

10.

Bouloumie A, Drexler HC, Lafontan M, et al. Leptin, the product of Ob gene, promotes angiogenesis. Circ Res. 1998;83:1059–66.PubMed

11.

Korda M, Kubant R, Patton S, et al. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol. 2008;295:1514–21.CrossRef

12.

Vecchione C, Maffei A, Colella S, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes. 2002;51:168–73.CrossRefPubMed

13.

Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784–92.CrossRefPubMed

14.

Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–7.CrossRefPubMed

15.

Nam SY, Lee EJ, Kim KR, et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes. 1997;21:355–9.CrossRef

16.

Rasmussen MH, Juul A, Hilsted J. Effect of weight loss on free insulin-like growth factor-I in obese women with hyposomatotropism. Obesity. 2007;15:879–86.CrossRefPubMed

17.

Nyomba BLG, Johnson M, Berard L, et al. Relationship between serum leptin and the insulin-like growth factor-I system in humans. Metabolism. 1999;48:840–4.CrossRef

18.

Delafontaine P, Ku L. Reactive oxygen species stimulate insulin-like growth factor I synthesis in vascular smooth muscle cells. Cardiovascular Res. 1997;33:216–22.CrossRef

19.

Schini VB, Busse R, Vanhoutte PM. Inducible nitric oxide synthase in vascular smooth muscle. Arzneimittelforschung. 1994;44:432–5.PubMed

20.

Koprowski H, Zheng YM, Heber-Katz E, et al. In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci U S A. 1993;90:3024–7.CrossRefPubMed

21.

National Cholesterol Education Program (NCEP) Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel. JAMA. 2001;285:2486–97.CrossRef

22.

Lohman TG, Roche AF, Martorell R, editors. Standardization of anthropometric measurements: The Airlie (VA) Consensus Conference. Champaign: Human Kinetics; 1988. p. 20–37.

23.

Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr. 1991;65:105–14.CrossRefPubMed

24.

Bonora E, Micciolo R, Ghiatas AA. Is it possible to derive a reliable estimate of human visceral and subcutaneous abdominal adipose tissue from simple anthropometric measurements? Metabolism. 1995;44:1617–25.CrossRefPubMed

25.

Bouza A, Bellido D, Rodríguez B, et al. Estimation of visceral and subcutaneous abdominal fat obese patients from anthropometric regression models. Rev Esp Obes. 2008;6:153–62.

26.

Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;8:412–9.CrossRef

27.

Ricart-Jané D, Llobera M, López-Tejero MD. Anticoagulants and other preanalytical factors interfere in plasma nitrate/nitrite quantification by the Griess method. Nitric Oxide. 2002;6:178–85.CrossRefPubMed

28.

Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed

29.

Donohue TJ, Dworkin LD, Lango MN, et al. Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. Circulation. 1994;89:799–09.PubMed

30.

Bibollet-Bahena O, Cui QL, Almazan G. The insulin-like growth factor-1 axis and its potential as a therapeutic target in central nervous system (CNS) disorders. Cent Nerv Syst Agents Med Chem. 2009;9:95–109.PubMed

31.

Sukhanov S, Higashi Y, Shai SY, et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:2684–90.CrossRefPubMed

32.

Muniyappa R, Walsh MF, Rangi JS, et al. Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci. 1997;61:925–31.CrossRefPubMed

33.

Evans JI, Maddux BA, Goldfine ID. The molecular basis for oxidative stress induced insulin resistance. Antioxid Redox Signal. 2005;7:1040–52.CrossRefPubMed

34.

Matsuzawa-Nagata N, Takamura T, Ando H, et al. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism. 2008;57:1071–7.CrossRefPubMed

35.

Gomez JM, Maravall FJ, Gomez N, et al. The IGF-I system component concentrations that decrease with ageing are lower in obesity in relationship to body mass index and body fat. Growth Horm IGF Res. 2004;14:91–6.CrossRefPubMed

36.

Poulos JE, Leggett-Frazier N, Khazanie P, et al. Circulating insulin-like growth factor I concentrations in clinically severe obese patients with and without NIDDM in response to weight loss. Horm Metab Res. 1994;26:478–80.CrossRefPubMed

37.

Efstratiadis G, Tsiaousis G, Athyros VG, et al. Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. Angiology. 2006;57(3):303–11.CrossRefPubMed

38.

Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236–2.CrossRefPubMed

39.

Andersson K, Gaudiot N, Ribiere C, et al. A nitric oxide-mediated mechanism regulates lipolysis in human adipose tissue in vivo. Br J Pharmacol. 1999;126:1639–45.CrossRefPubMed

40.

Pardina E, Lecube A, Llamas R, et al. Lipoprotein lipase but not hormone-sensitive lipase activities achieve normality after surgically induced weight loss in morbidly obese patients. Obes Surg. 2009;19:1150–8.CrossRefPubMed

41.

Cleland SJ, Sattar N, Petrie JR, et al. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci. 2000;98:531–5.CrossRefPubMed

42.

Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.CrossRefPubMed

43.

Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol. 2000;35:S1–7.CrossRefPubMed

44.

Brennan AM, Li TY, Kelesidis I, et al. Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: a prospective cohort study. Diabetologia. 2007;50:1178–85.CrossRefPubMed

45.

Chan DC, Watts GF, Ng TW, et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem. 2005;51:578–5.CrossRefPubMed

46.

Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:4–12.PubMed

47.

Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004;68:975–81.CrossRefPubMed

48.

Abbasi F, Chang SA, Chu JW, et al. Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Am J Physiol Regul Integr Comp Physiol. 2006;290:139–44.

49.

Mantzoros CS, Li T, Manson JE, et al. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4542–8.CrossRefPubMed

50.

Coughlin CC, Finck BN, Eagon JC, et al. Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity. 2007;15:640–5.CrossRefPubMed

Title: The Relationships Between IGF-1 and CRP, NO, Leptin, and Adiponectin During Weight Loss in the Morbidly Obese
Authors: Eva Pardina
Roser Ferrer
Juan Antonio Baena-Fustegueras
Albert Lecube
Jose Manuel Fort
Víctor Vargas
Roberto Catalán
Julia Peinado-Onsurbe
Publication date: 01-05-2010
Publisher: Springer-Verlag
Published in: Obesity Surgery / Issue 5/2010
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-010-0103-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Relationships Between IGF-1 and CRP, NO, Leptin, and Adiponectin During Weight Loss in the Morbidly Obese

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2010

Hepatic Gene Expression of Caucasian and African-American Patients with Obesity-Related Non-Alcoholic Fatty Liver Disease

Comparison of Early and Late Changes in Immunoglobulins and Acute Phase Reactants after Laparoscopic Adjustable Gastric Banding in Patients with Morbid Obesity

Bileopancreatic Diversion with Duodenal Switch Lowers Both Early and Late Phases of Glucose, Insulin and Proinsulin Responses After Meal

Breast Contouring in Postbariatric Patients: A Technique Selection Algorithm

One Year Improvements in Cardiovascular Risk Factors: a Comparative Trial of Laparoscopic Roux-en-Y Gastric Bypass vs. Adjustable Gastric Banding

Exercise Following Bariatric Surgery: Systematic Review